AstraZeneca recognizes Mental Health Month

Posted By

Michele Meixell

By Jamie Mullen, MD, Executive Director, Clinical Development, AstraZeneca

This entry is the second of a two-part series focusing on mental health awareness. The first entry, providing background on Mental Health Month and the impact of mental health disorders can be found here.

Since 1949, May has been designated Mental Health Month, providing an opportunity to increase education and awareness around mental illness.

AstraZeneca has been committed to the mental health space for over 50 years. Our efforts range from helping raise awareness for mental health conditions and the need for patient access to treatment and services to developing treatment options that help patients manage mental health conditions.

And yet, we know that we can’t do it alone. AstraZeneca recognizes and supports the important work being done by groups including the Depression and Bipolar Support Alliance, Mental Health America, National Alliance on Mental Illness, and the National Council for Community Behavioral Healthcare that strive to provide support and services for patients with and physicians who treat mental illnesses.

There is more to be done. AstraZeneca continues to look to the science to help discover and bring to bear treatment options in neuroscience – including neurology, pain and psychiatry.  Earlier this year we created a new unit in Boston that allows our scientists to tap into the best available external science while sharing cost, risk and reward with other research partners active in the field.

You can learn more about AstraZeneca’s focus on neuroscience and other key areas of interest for innovation here. For more information about Mental Health Month.